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Abstract 
Introduction: Cholangiocarcinoma (CCA) is an epithelial cell malignancy arising from bile ducts 
and/or peribiliary glands. Even though it is considered as a rare neoplasm, its incidence is raising, 
particularly in developed countries. Prognosis is generally poor with few patients who present the 
inclusion criteria for surgery (the mainstay treatment for this tumour). Several genetic alterations 
potentially driving tumour progression have been described, representing a possible target for new 
compounds. 
Areas covered: A clinical trial search in Clinicaltrials.gov encompassing a literature search in 
PubMed and ASCO/ESMO Websites was undertaken in March 2016.  
Expert opinion: Notwithstanding a large number of drug tested, results are still disappointing. The 
main reasons could be the low number of patients enrolled in trials, and the lack of a patient 
selection based on the biological profile of the tumours. Potential active drugs could have been 
discharged simply because beneficial in a particular subgroup of patients and not in un unselected 
population. The future direction of the research should consider biomarker evaluation in order to 
describe the genetic alteration/s that drive tumour progression and aggressiveness and the 
mechanisms of drug resistance. Finally, it will be of great interest to consider the results of 
immunotherapy whenever available. 
 
 
 
 
 
 
Article highlights 
• Cholangiocarcinoma is a rare cancer and its incidence is raising particularly in developed 
countries. Many genetic alterations have been described, giving rationale for the 
development of new treatment strategies 
• Anti-EGFR therapies have been extensively studied in cholangiocarcinoma patients. 
Notwithstanding encouraging preliminary results, comparison trials did not demonstrate 
superiority of cetuximab or panitumumab plus chemotherapy versus chemotherapy alone. A 
new pan-HER oral inhibitor is being tested 
• Several specific inhibitors directed to mTor, ABL, PI3K/AKT, Farnesyltransferase, 
proteasome, and VEGF failed to demonstrate significant clinical activity in unspecific 
patient population.  
• Results from trial selecting patients with specific genetic alterations (FGFGR, IDH, ALK, 
ROS1, NTRK) or from trial that explore the role of drugs with new mechanisms of action 
(oxygen modulators, pan-IDH1 mutant inhibitor, PARP 1/2 inhibitor) will help researchers 
to shed light on the mechanisms underlying tumour progression 
• The characterization of the genetic profile of each single tumour will pave the way for 
personalized and hopefully efficacious therapies. 
 
  
1.1. Introduction 
Cholangiocarcinoma (CCA) is an epithelial cell malignancy arising from intrahepatic (IH) and 
extrahepatic (EH) bile ducts and/or the peribiliary glands [1]. EH disease represents about 40%, 
perihilar disease 50% and IH disease less than 10% of cholangiocarcinoma cases. The incidence is 
globally raising, particularly in developed countries, accounting for up to 2 new cases every 
100.000 inhabitants per year [1,2]. The mainstay treatment for this type of neoplasia is surgery. 
However, only approximately one half of the patients is suitable for resection and surgical 
techniques are rather complex, often necessitating lobar hepatic and bile duct resection, regional 
lymphadenopathy, and Roux-en-Y hepaticojejunostomy. Liver transplantation with neoadjuvant 
chemoradiation is a valid therapeutic alternative. However, only few patients present the strict 
inclusion criteria for transplantation. As a whole, prognosis of CCA is generally bad, with mortality 
rate of 1.4 per 100.000 inhabitants per year, an average. 
After the publication of the ABC-02 study results [3] chemotherapy with Cisplatin and gemcitabine 
is considered the standard of care in locally advanced or metastatic CCA, with some alternatives 
equally considered as standard of care such as gemcitabine/oxaliplatin, or 
Gemcitabine/Capecitabine. Notwithstanding positive results with chemotherapy, median survival is 
poor with a life expectancy of no more than 12 months. Contemporary research techniques allowed 
the identification of several genetic changes contributing to the selective growth advantage of CCA 
cancer cells[1]. The most studied signalling networks in CCA biology is the RAS-MAPK pathway, 
followed by VEGF, PI3K/mTOR, HER2/neu and MET pathways. Thus, the number of clinical 
trials with targeted therapy alone or in combination with traditional chemotherapy is expanding, and 
new drugs are in early stages of investigation. 
In this review we focus the attention on new drugs and new strategies currently under investigation 
in the treatment of biliary tract carcinomas. Where not otherwise specified, reported studies 
included patients with either IH, and EH, and peribiliary glands. 
2. Anti HER family 
2.1. Agents at later stage of development 
2.1.1. Anti-EGFR monoclonal antibodies: cetuximab and panitumumab 
The EGFR pathway has been identified as a promising molecular target in CCA. In fact, 
overexpression of EGFR was found in 38%–100% of the tumour samples, almost all in the gene 
sequence coding for the tyrosine kinase domain found in exon 21 [4]. 
Cetuximab (Erbitux™, Merck) is a recombinant human-mouse chimeric IgG1 monoclonal antibody 
binding EGFR with high affinity approved for the treatment of patients with metastatic colorectal 
cancer (CCR) and head and neck cancer [5-7].  
The efficacy of cetuximab in CCA was firstly reported in a retrospective analysis evaluating the 
outcomes of five patients with stage IV or not completely resected tumours receiving cetuximab-
containing therapy. After treatment, four patients experienced a clinical response (one complete) 
and one disease stabilization. [8]. Notwithstanding these encouraging results, subsequent and larger 
clinical trials reported contrasting results. In a multi-centre phase II trial 44 patients with CCA 
received cetuximab and gemcitabine. The study met its primary endpoint as six months progression 
free survival (PFS) was 47%. Median overall survival (OS) was 13.5 months and nine patients 
(20.4%) had partial response (PR) with an overall disease-control rate (DCR) of 79.5% [9]. In a 
non-comparative, open-label, randomised phase 2 trial, recruiting patients with non-resectable or 
metastatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma, 150 patients were 
randomly assigned to receive gemcitabine and oxaliplatin (GEMOX) with or without cetuximab. 
Clinical outcomes resulted to be comparable in the two arms as median PFS was 6·1 months in the 
chemotherapy plus cetuximab group and 5.5 months in the chemotherapy alone group, whereas 
median overall survivals were 11 vs 12.4 months, respectively [10]. 
Cetuximab treatment seems to be beneficial particularly in patients with intrahepatic CCA. In fact 
in an open-label pilot study of nine patients progressing after GEMOX the addiction of cetuximab 
permitted to obtain a tumour shrinkage in two (22%) of them [11]. Gruenberger et al published a 
single-arm phase II study of GEMOX and cetuximab demonstrating an overall response rate of 
63%, including 3 patients with a complete response. The majority of the patients in this trial had 
intrahepatic cholangiocarcinoma (60%). The study did not limit recruitment to patients with KRAS 
wild-type tumours, and interestingly, partial responses were observed in two of the three patients 
with KRAS mutant tumours. The interim analysis of the first 36 patients revealed an improvement 
in PFS rate at four months of the experimental arm vs placebo (61 vs. 44%) [12]. 
Recently, the results of a randomised, phase II study of GEMOX with or without cetuximab 
conducted in Asian countries confirmed that the combination was not statistically superior to 
chemotherapy alone. Response rate, primary endpoint of the study, did not differ between the two 
arms (27% vs 15% with vs without cetuximab, respectively, p=0.12). Median PFS were 6.7 vs 4.1 
(p=0.05) and median OS 10.6 vs 9.8 months (p=0.91) [13]. Interestingly, KRAS status seemed not 
to influence clinical outcomes. Key results of the above described trials are summarized in Table 1. 
Panitumumab (Vectibix™, Amgen) is a fully humanized IgG2 monoclonal antibody. It was 
generated in transgenic strains of mouse and modified to express human immunoglobulin genes 
(XenoMouse). Panitumumab is approved only for the treatment of metastatic colorectal cancer 
patients [14].  
In CCA, encouraging results were reported in 42 patients with KRAS wild-type tumours enrolled in 
a phase II trial exploring the activity of the combination of GEMOX with capecitabine and 
panitumumab. Overall response rate (ORR) was 33% with a DCR of 86%, median PFS of 8.3 
months,6-month PFS rate of 71%, and a median OS of 9.8 months [15]. These results were 
furtherly confirmed in a phase II study enrolling 31 patients with locally advanced or metastatic 
KRAS wild-type CCA treated with GEMOX + panitumumab: ORR was 45%, median PFS 10.6 
months and median OS 20.3 months [16].  
A phase II study enrolling 35 patients with advanced CCA and treated with gemcitabine, irinotecan 
and panitumumab reported a ORR of 31%, a median PFS of 9.7 months with a 5-month PFS rate of 
69% (primary aim of the study) and a median OS of 12.9 months. Interestingly, patients were 
recruited regardless the KRAS status of their tumours, obtaining clinical outcomes similar to those 
reported from patients with KRAS wild-type tumours [17].  
These encouraging results were not confirmed in an Italian open-label phase II trial randomising 
patients with advanced KRAS wild-type CCA to receive GEMOX with (arm A) or without (arm B) 
panitumumab. Primary endpoint of the study was PFS. Eighty-nine patients (45 in arm A and 44 in 
arm B) were enrolled between June 2010 and September 2013. After a median follow-up of 10.1 
months, the median PFS was 5.3 months in arm A and 4.4 months in arm B (p= 0.27). No survival 
difference was observed: median OSs were 9.9 vs 10.2 months, respectively (p= 0.42). In a pre-
planned subgroup analysis, no difference in PFS was demonstrated according to the site of the 
primary tumour [18]. 
An ongoing trial conducted in Denmark aims to compare PFS of patients with advanced CCA 
randomly allocated to chemotherapy group (GEMOX + capecitabine) or to chemotherapy plus 
panitumumab. Patients are enrolled regardless the KRAS status of their tumours. Estimated 
enrolment is 70 patients, but the study is not yet recruiting (ClinicalTrials.gov Identifier: 
NCT00779454). Key results of the above described trials are summarized in Table 2. 
 
2.1.2. Anti-EGFR TKIs: erlotinib 
Erlotinib (Tarceva™) reversibly binds the intracellular kinase domain of EGFR inhibiting the ATP-
dependent activation of downstream pathway enzymes. It is currently approved for the treatment of 
EGFR mutant non-small cell lung cancer (NSCLC) as single agent and of pancreatic cancers in 
combination with gemcitabine [19].  
A potential efficacy of erlotinib in CCA was firstly reported as single agent in a phase II study 
enrolling 43 patients at any line of therapy. Three partial responses were observed, for an overall 
response rate of 8% [20]. Data from a randomized, phase III, placebo controlled trial recruited a 
total of 285 patients who received GEMOX with erlotinib or placebo. Median PFS of the 
experimental arm was 5.8 months vs 4.2 months of the placebo group (p=0.08). Median OSs were 
9.5 months and were similar in both groups [21]. The combination of erlotinib and bevacizumab 
was tested in a phase II, multicentre study enrolling 49 patients with advanced CCA. Six patients 
obtained confirmed PR, for an ORR of 12%, whereas median OS was 9.9 months, and median TTP 
was 4.4 months [22]. Finally, a phase II trial (NCT01093222) evaluated the combination of 
sorafenib with erlotinib in patients with locally advanced, unresectable or metastatic CCA. 
Treatment was administered to 34 patients resulting in a median PFS of 2 months and in a median 
OS of 6 months. Treatment was toxic, with an incidence of SAE in about 50% of the patients, 
including 17% of toxic deaths, 8 % of which for gastrointestinal toxicity or sepsis. 
2.1.3. Anti HER2 monoclonal antibodies: trastuzumab 
Trastuzumab is a humanized monoclonal antibody that selectively binds HER2 receptor. It is 
currently approved in the treatment of breast and gastric cancer patients [23,24].HER-2 
overexpression has been found in about 5% of CCA, justifying the interest of the clinicians towards 
HER2 inhibitors in this setting [25,26]. 
Some sporadic experiences of trastuzumab treatment in patients with CCA have been reported in 
literature as single agent or in combination with paclitaxel [27,28]. After having screened 53 
patients with locally advanced or metastatic gallbladder cancer or CCA, a phase II study submitted 
a total of four patients to trastuzumab monotherapy. Two out of the three evaluable patients 
responded, with an ORR of 66.6%. No information about the histology of the recruited patients was 
available (NCT00478140). These results were not confirmed in a retrospective analysis of five 
patients with advanced gallbladder or CCA harbouring HER2 mutations or overexpression and 
treated with anti HER2therapy: while patients with gallbladder tumours beneficiated from therapy, 
no response among patients with CCA was observed and all the patients progressed while on 
treatment with trastuzumab [29]. 
2.1.4. Anti-HER2 TKIs: lapatinib 
Lapatinib is an orally active, dual inhibitor of HER2 and EGFR approved in breast cancer patients. 
In in vitro studies lapatinib demonstrated superior inhibiting activity than trastuzumab in CCA cell 
lines [26]. 
Despite preclinical evidences, lapatinib did not show any activity in CCA. A phase II study with 
lapatinib was stopped early as no clinical response has been observed in the first nine enrolled 
patients [30], whereas in another study the response rate of 17 patients with CCA was 0%, with a 
median PFS of 1.8 months and a median OS of 5.2 months [31]. It has to be underlined, however, 
that in both studies no biomolecular selection has been made before patients enrolment. 
2.2. Novel anti-HER agents 
2.2.1. ASLAN001 
ASLAN001 (Aslan Pharmaceuticals, Array-Biopharma), a novel oral pan-HER inhibitor, has shown 
clinical activity in both HER2-positive and EGFR-positive tumours. ASLAN001 is currently under 
development in HER2 expressing-cancers such as breast and gastric cancers. 
A phase II multicentre study is recruiting patients with advanced or metastatic CCA (excluding 
peribiliary glands) who progressed after at least 1 line of systemic therapy to receive ASLAN001. 
Primary endpoint of the study is ORR, and secondary endpoints are the description of the safety 
profile of the drug, duration of response, PFS, OS, and DCR according to EGFR/HER2 status of the 
tumours (NCT02609958). The study will enrol a total of 25 patients in Asian countries, and it will 
be stopped if any response is observed in the first 10 patients. Recruitment has started in October 
2015 and it is estimated to end in June 2017. 
No information on ASLAN001 safety profile is yet available. 
 
3. mTOR inhibitors 
3.1. Everolimus 
The mTOR pathway is known to be up-regulated in many cancer types, and preclinical evidences 
indicate that its inhibition may be effective in the treatment of CCA [32,33]. To date, everolimus is 
authorized for the treatment of patients with advanced breast cancer, neuroendocrine tumour and 
renal cell carcinoma. [34-37]. 
Few experiences of anti mTOR therapy in patients with CCA have been reported. A phase II Italian 
study (EUDRACT 2008-007152-94) explored the role of everolimus 10mg daily in locally 
advanced or metastatic CCA patients refractory to standard chemotherapy. Primary end points of 
the study were DCR and ORR that resulted to be 44.7% and 5.1%, respectively. One patient had a 
partial response and one had a complete response lasting more than 8 months. Median PFS was 3.2 
months, median OS was 7.7 months, and median TTP was 2.0 months [38]. A phase I study 
evaluated the combination of everolimus with gemcitabine (Cohort I) and with gemcitabine and 
cisplatin (Cohort II) in patients with advanced tumours (including CCA) refractory to standard 
chemotherapy. As an expansion cohort, 10 patients with advanced gallbladder cancers were treated 
with the maximally tolerated dose of cohort II: everolimus 5 mg on Monday/Wednesday/Friday, 
gemcitabine 600 mg/sqm, and cisplatin 12.5 mg/sqm. In this latter subgroup, six patients 
experienced a disease stabilization and four progressed [39].  A phase I trial conducted at Mayo 
Clinic in Rochester (USA) is exploring the safety profiles of sirolimus with gemcitabine and 
cisplatin in patients at high risk for cholangiocarcinoma recurrence after liver transplant or surgery 
(NCT01888302). Trial is ongoing and estimated primary completion date is September 2016.Two 
phase II studies evaluating the efficacy of everolimus as monotherapy in CCA patients initiated in 
2009 (NCT00973713) and in 2012 (NCT01525719). No information on the results of these two 
trials is yet available. 
Everolimus is generally well tolerated, with most common adverse events being stomatitis, rash, 
fatigue, diarrhoea, nausea, and decreased appetite. A less common, life-threatening adverse event is 
non-infectious pneumonitis (presenting as an acute deterioration in respiratory function with ground 
glass–appearing or patchy opacities on computed tomography scans). 
 
4. Anti neoangiogenic therapies 
4.1. Monoclonal antibodies: bevacizumab and ramucirumab 
Bevacizumab (Avastin™, Roche) is a recombinant, fully humanized iGg1 monoclonal antibody 
against VEGF A isoform approved for the treatment of patients with metastatic colorectal cancer, 
renal cell carcinoma, glioblastoma and ovarian cancer [40-43].  
As far as CCA is concerned, the role of bevacizumab in combination with gemcitabine and 
oxaliplatin was explored in a phase II study. Study endpoint was not reached as 6-month PFS rate 
was 63% (target: 70%), whereas median PFS was 7 months, ORR 40%, and DCR 69% [44]. The 
combination of FOLFIRI (fluorouracil, folinic acid, and irinotecan) with bevacizumab as second-
line treatment in patients with metastatic intrahepatic cholangiocarcinoma resulted in one complete 
response, four partial response, and six stable disease for an ORR of 38.4% and a DCR of 
84.5%.The treatment was well tolerated [45]. 
The combination of bevacizumab and erlotinib was explored as first-line treatment in 53 patients 
with metastatic or unresectable biliary tumors. Among the 49 evaluable patients, six (12%) had a 
confirmed partial response, 25 a disease stabilization (51%), and 18 progressed. Median OS and 
TTP were 9.9 and 4.4 months, respectively [46]. The same combination was furtherly tested in 102 
CCA patients with refractory tumours. ORR was 6%, median PFS 2.2 months and OS 4.3 months 
[47]. 
Concerning experimental studies, a multicentre phase II study of gemcitabine, capecitabine and 
bevacizumab as first-line treatment for locally advanced or metastatic adenocarcinoma of the gall 
bladder or biliary ducts recruited 50 patients in USA (NCT01007552). Study was terminated on 
May 2015 and results are not yet available. A phase I study aimed to evaluate safety profile of 
proton therapy and concurrent bevacizumab biotherapy (NCT00426829). This trial was terminated 
early due to low accrual and no safety data are available. 
Ramucirumab (Cyramza™, Eli Lilly) is a fully human IgG1 monoclonal antibody targeting the 
extracellular domain of VEGFR-2. Preclinical models showed that ramucirumab might selectively 
bind to and inhibit the human VEGFR-2 with a much greater affinity than its natural ligand, 
resulting in significant antitumor activity in a wide range of malignancies [48]. Ramucirumab is 
approved for the treatment of NSCLC, gastric and colorectal cancer patients. A phase II trial is 
studying ramucirumab for advanced pre-treated biliary cancers. Recruitment of 50 patients started 
on December 2015 and is expected to end on December 2019 (NCT02520141).  
4.2. Multi-TKI: cediranib, regorafenib, sorafenib, sunitinib, pazopanib 
Cediranib (AstraZeneca) is a potent TKI inhibiting all three VEGF receptors (VEGFR-1, -2, -3), c-
kit, and platelet derived growth factor receptor alpha and beta (PDGFR-α, PDGFR-β). It inhibits 
VEGF-induced angiogenesis showing anti-neoplastic effects in a range of tumour xenograft mouse 
models [49]. Cediranib has shown promising results in several phase-I clinical trials in patients with 
various solid tumours [50]. A multicentre, placebo-controlled, randomised phase II study assessed 
the effect on PFS of the combination of cisplatin and gemcitabine with oral cediranib 20 mg once 
daily or placebo in 124 chemo-naïve patients with locally advanced or metastatic CCA. After a 
median follow-up of 12.2 months, median PFS was 8·0 months in the cediranib group and 7·4 
months in the placebo group (HR 0·93, 95% CI 0·65-1·35; p=0·72). Patients who received 
cediranib had more grade 3-4 toxic effects: hypertension (37% vs21%; p=0·05), diarrhoea (13% vs 
3%; p=0·05); and fatigue (24% vs 11%; p=0·04) [51]. 
Regorafenib (STIVARGA™, Bayer) is an oral multikinase inhibitors with activity against selected 
tyrosine kinases (VEGFR2-3, TIE-2, PDGFR, FGFR, RET and c-Kit) as well as a signal 
transduction inhibitor of the RAF/MEK/ERK pathway. It demonstrated preclinical and clinical 
activity in several tumours, including colorectal cancer for which treatment of refractory patients 
has been authorized [52,53]. Three phase II trials are now exploring the role of regorafenib in 
patients with metastatic or unresectable CCA as single agent in refractory tumours (NCT02115542), 
as second-line treatment (NCT02053376) or in combination with chemotherapy (GEMOX) in first-
line setting (NCT02386397). Results are waited for the end of 2018. Toxicity profile of regorafenib 
is similar to that of other multi TKI targeting mainly VEGFR, and in particular fatigue, 
hypertension, and hand-foot skin reactions. 
Sorafenib (Nexavar™, Bayer) is approved for the treatment of patients with hepatocarcinoma and 
metastatic renal cell cancer[54,55]. The activity of sorafenib as first-line treatment in patients with 
gallbladder carcinomas was evaluated in a phase II trial terminated after the first stage of accrual of 
25 patients as no response was recorded. Median PFS was 3 months and median OS was 9 months 
[56]. A Phase I/II study explored the combination of GEMOX with sorafenib in CCA patients. Due 
to treatment toxicity, study was terminated after completion of the phase I (9 patients enrolled) and 
thus no clinical information is available. Toxicities were predominantly gastrointestinal (vomiting, 
diarrhoea, dehydration), fever, peritoneal infection and dyspnoea. (NCT00955721). The 
concomitant administration of sorafenib and erlotinib in patients with advanced gallbladder 
carcinoma or CCA resulted toxic (SAE were reported in 50% of the patients including a toxic 
death) with poor anti-tumour activity as median PFS was 2 months and median OS 6 months (NCT 
01093222). 
Sunitinib (Sutent™, Pfizer) is a multi TKI mainly inhibiting VEGFR family [57] approved for the 
treatment of patients with GIST, metastatic renal cell carcinoma, and pancreatic neuroendocrine 
tumours [58-60]. A single phase II study of sunitinib as second-line treatment in patients with IH 
carcinomas has enrolled 51 patients in French institutions. Primary endpoint is OS and study 
completion date is estimated to be September 2016 (NCT01718327). 
Pazopanib (Votrient™, Novartis) is approved for the treatment of patients with metastatic renal cell 
carcinoma and soft tissue sarcoma [61,62]. A phase II, single-arm study is assessing the impact of 
pazopanib and gemcitabine on the overall response rate of 46 patients with unresectable or 
metastatic CCA. This study is conducted in Greece, started on June 2009 as is expected to end in 
November 2016 (NCT01855724). A phase I study aims to describe the safety profile of pazopanib 
and trametinib, a MEK inhibitor in patients with advanced solid tumours, including CCA. The study 
is expected to enrol a total of 111 patients. Results are awaited as study was supposed to end on 
April 2016 (NCT01438554). The most common toxicities of pazopanib are similar to those reported 
for sorafenib and sunitinib, with gastrointestinal effects (nausea, vomiting, diarrhoea) and fatigue as 
the most frequent side effects 
 
5. Anti FGFR therapy 
5.1. BGJ398 (infigratinib) 
Preclinical studies have demonstrated that aberration in fibroblast growth factor receptor (FGFR) 
activity is implicated in the development and progression of CCA and other malignancies. Thus, its 
inhibition might have an important therapeutic potential as demonstrated by the pan-FGFR inhibitor 
BGJ398 (Infigratinib, Novartis Pharmaceuticals) either in CCA cell lines and in murine models 
[63]. Moreover, FGFR2 fusion events are present in up to 17% of intrahepatic CCAs and appear to 
predict sensitivity to FGFR inhibitors even after progression on chemotherapy [64]. On this basis, a 
phase II multicentre, single arm study of oral BGJ398 in patients with advanced or metastatic CCA 
with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to 
platinum-based chemotherapy is ongoing. Primary endpoint is ORR and accrual of 55 patients is 
expected to end on July 2018 (NCT02150967). 
5.2. ARQ087 
ARQ087 (ArQule) is an orally bioavailable compound and a dual kinase inhibitor that binds to 
inactive form of FGFR1 and FGFR2 and potently inhibits the active form of FGFR1 and FGFR2. A 
phase 1/2 study evaluating the potential role of ARQ087 in patients with advanced solid tumours 
(including CCA) with FGFR genetic alterations is ongoing. The study is designed to explore the 
safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ARQ087 as 
single agent in 120 patients refractory to standard therapies and is expect to end on June 2017 
(NCT01752920). 
 
6. Other oral inhibitors 
6.1. ALK inhibitors 
Ceritinib (Zykadia™, Novartis) is an oral, small-molecule, ATP-competitive, tyrosine kinase 
inhibitor of anaplastic lymphoma kinase (ALK) approved for the treatment of ALK-positive non-
small cell lung cancer (NSCLC) patients failing crizotinib. The potential role of ceritinib in ALK-
activated gastrointestinal tumours is being explored in two phase II studies, the first including 
patients with ALK-activated gastrointestinal malignancies refractory to standard chemotherapies, 
the second including ROS1 and /or ALK over-expressed advanced intrahepatic or hilar CCA. 
(NCT02638909 and NCT02374489). Both studies started on 2015 and preliminary results are 
waited for the end of 2017-beginnig 2018. Ceritinib toxic effects included diarrhoea, vomiting, 
dehydration, elevated aminotransferase levels, and hypophosphatemia. 
Another selective, ATP-competitive ALK TKI is Entrectinib (Ignyta). This small molecule is an 
orally bioavailable, pan-Receptor tyrosine kinases and ROS1 inhibitor. In pre-clinical models, 
entrectinib has shown antitumor efficacy in ALK- and ROS1-driven tumours [65]. In humans, a 
Phase I dose-escalation study (ALKA-372-001) in subjects with previously treated, advanced solid 
tumours harbouring neurotrophic receptor tyrosine kinase (NTRK)1, ROS1 or ALK alterations 
resulted in 22% of ORR [66]. A Phase 1/2 study is assessing the role of entrectinib in subjects with 
previously treated, locally advanced or metastatic solid tumours including CCA with NTRK1 -2 -3, 
ROS1 or ALK molecular alterations (NCT02568267). This study will enrol 300 patients and is 
expected to end in 2018.Entrectinibis generally well tolerated, with side effects comprising 
asthenia, paraesthesia, nausea, myalgia, dysgeusia, vomiting, arthralgia, diarrhoea and attention 
disturbance. 
6.2. Anti ABL 
Bosutinib (Bosulif™, Pfizer), a potent ATP-competitive dual Src/AblTKI, is approved for the 
treatment of Philadelphia chromosome-positive chronic myeloid leukaemia patients and 
demonstrated anti-tumour activity against several tumour xenograft [67-69]. In clinical trials, while 
bosutinib showed promising efficacy prolonging TTP in pre-treated patients with locally advanced 
or metastatic breast cancer [70], its unfavourable risk-benefit ratio and limited activity in other 
malignancies (including CCA) did not warrant further investigation [71,72]. 
Imatinib (Glivec™, Novartis) is the first TKI authorized for the treatment of patients with CML and 
GIST. Its impressive activity in those two malignancies led to explore its role in other tumours. A 
phase II study is testing the association of imatinib with 5-FU/leucovorin in patients with advanced 
carcinoma of the gallbladder and bile duct. The study has been completed in 2010 but no results 
have been published, yet (NCT01153750). Finally, a bicentric phase II trial of imatinib as second-
line treatment in CCA patients was terminated prematurely due to poor recruitment rate and very 
limited efficacy [73].  
6.3. MEK inhibitors 
Trametinib (Mekinist™, GlaxoSmithKline) is a mitogen-activated, extracellular signal-regulated 
kinase (MEK) inhibitor 1 and 2 approved for the treatment of patients with tumours harbouring 
BRAF V600E or V600K gene mutations. Focusing on patients with CCA, as already mentioned, a 
phase I study is exploring the association of trametinib with pazopanib (see pazopanib section; 
NCT01438554), whereas a randomized phase II trial is aiming to assess the role of trametinib alone 
or in combination with chemotherapy in patients with refractory CCA (NCT02042443). The study 
recruited 89 participants and results are awaited for the end of 2016. The most common adverse 
events associated with trametinib are rash, diarrhoea, peripheral oedema, fatigue, and dermatitis.  
Another oral, selective inhibitor of the MEK1/MEK2 kinases is selumetinib (Astra Zeneca) in 
development particularly for NSLCL tumours [74,75]. Very recently, the results of a phase I study 
of selumetinib with cisplatin and gemcitabine in CCA patients have been published: dose limiting 
toxicity (DLT) was 75 mg twice daily, among eight evaluable patients three had a partial response 
and five stable disease, with a median PFS of 6.4 months [76]. Selumetinib is not currently under 
development in CCA patients. The most common toxicities observed were rash, mild to moderate 
diarrhoea, fatigue and oedema.  
6.4. PI3K inhibitors/AKT inhibitors 
Buparlisib (Novartis) is a pan-PI3K inhibitor preventing the PI3K–AKT–mTOR pathway activation 
[77] that demonstrated preliminary activity in preclinical models of solid tumours [78]. In clinical 
studies, some results have been reported in lymphoma and in breast cancer patients. A phase II trial 
in patients with various tumours (including CCA) harbouring PI3K activating mutations has been 
proposed in 2011, but it was closed prematurely due to lack of accrual (NCT01501604). The most 
common treatment-related adverse events reported were rash, increased transaminase levels, 
increased blood insulin levels, increased eosinophil, and hyperglycaemia. 
MK2206 (Merck) is an oral pan-AKT inhibitor showing some activity in biliary cancer tumour 
models [79,80]. Promising results have been reported in clinical studies enrolling patients with 
breast cancer and multiple myeloma. A phase II study in refractory CCA patients treated with 
MK2206 as monotherapy reported two disease stabilization out of eight treated patients. Authors 
concluded that even though therapy was well tolerated, MK2206 alone has limited activity in this 
patient subset and must be eventually be tested in combination with other target agents or standard 
chemotherapy [81]. 
6.5. Farnesyltransferase inhibitor 
Lonafarnib (Merck) is an oral selective farnesyltransferase inhibitor (FTI) [82]. In preclinical 
studies, lonafarnib has shown to be active against a broad spectrum of tumour cell lines and tumour 
xenografts in nude mice [83]. Contrasting results have been reported in patients with breast cancer, 
glioblastoma, head and neck cancer, and ovarian cancer. A randomised phase II trial aiming to 
compare lonafarnib with surgery vs surgery alone in patients with primary liver cancers including 
CCA was proposed in 2011. The trial has been withdrawn prior to enrolment (NCT00020774)  
Another orally bioavailable non-peptidomimetic FTI is Tipifarnib (Zarnestra™, Johnson & 
Johnson) which demonstrated preclinical and clinical activity against acute myeloid leukemia 
(AML) and breast cancer [84]. A phase I study of tipifarnib and herceptin in patients with advanced 
cancer including CCA enrolled 24 patients (NCT00005842). Preliminary safety results were 
presented at the Annual meeting of the American Society of Clinical Oncology (ASCO) in 2001 
[85]. The most common grade 3-4 toxicities included neutropenia, nausea, and vomiting.  
6.6. Proteasome inhibitor  
The proteasome inhibitor bortezomib (Velcade™, Janssen-Cilag), demonstrated tumour cell growth 
suppression and apoptosis in several tumour cell lines [86]. While it has been approved for the 
treatment of multiple myeloma (MM) and mantle cell lymphoma (MCL) patients, bortezomib 
treatment in solid tumours have generally produced less promising results as it failed to demonstrate 
clinical activity in NSCLC, head and neck cancer, ovarian cancer, hepatocellular cancer, gastric 
cancer, colorectal cancer, and prostate cancer patients. A phase II trial treated patients with 
unresectable or metastatic gallbladder or CCA with bortezomib as single agent. A Simon two-stage 
design was used. The trial was discontinued early because after the first 20 patients only one 
unconfirmed partial response was recorded. Median TTP was 5.8 months and median OS was 9 
months with 6-month and 1-year survival rates of 70% and 38%, respectively. Author concluded 
that despite the treatment did not result in objective response, the rate of stable disease and time to 
progression benchmark is encouraging, so that further development of bortezomib in combination 
with other therapies should be considered in this setting [87]. The most frequently reported AEs 
were thrombocytopenia and peripheral neuropathy. 
 
7. Multitarget inhibitors 
Vandetanib (CAPRELSA™, AstraZeneca) is an orally available receptor TKI that inhibits EGFR, 
VEGFR-2, RET, BRK, Tie2, members of the EPH receptor and Src kinase families in tumour cells 
and endothelial cells and that demonstrated some anti-tumour activity in preclinical studies [88]. 
Vandetanib showed encouraging clinical activity in various tumours and it is approved for the 
treatment of patients with medullary thyroid cancer. Its role in CCA patients has been evaluated  in 
a phase II study randomizing advanced patients to receive vandetanib 300 mg monotherapy versus 
vandetanib 100 mg plus gemcitabine versus gemcitabine plus placebo. The primary end point was 
PFS; secondary end points were ORR, DCR, OS and safety outcomes. A total of 173 patients were 
recruited at 19 centres across Italy. Median PFS were 105 days, 114 days and 148 days, respectively 
(p = 0.18). No statistical difference between treatments was observed for secondary end points. 
Finally, the proportion of patients reporting adverse events was similar for the three groups (89.3%-
96.6%) [89]. The most common adverse events include diarrhoea, rash, nausea, hypertension, 
fatigue, abdominal pain, hypocalcaemia, hypoglycaemia, and QT prolongation. More rarely, 
vandetanib administration could be linked to the onset of interstitial lung disease, ischemic 
cerebrovascular events, serious haemorrhagic events, heart failure, hypothyroidism, hypertension, 
and reversible posterior leukoencephalopathy syndrome.  
Merestinib (LY2801653, Lilly) inhibits MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2, 
MKNK1/2, MET, and HGF [90,91]. A phase II study is randomizing patients with advanced CCA 
to receive cisplatin, gemcitabine and either ramucirumab or merestinib as first-line treatment. The 
primary endpoint of the trial is PFS, the main secondary endpoints OS and ORR. Enrolment of 300 
patients started on May 2016 and is expected to end on April 2018 (NCT02711553). Finally, a 
phase Ia/Ib study of ramucirumab in Combination With merestinib or abemaciclib in advanced 
cancers has been opened in April 2016 and results are waited for August 2019 (NCT02745769) 
Cabozantinib (Cometriq™, Exelixis) is a TKI mainly inhibiting MET with activity against 
VEGFR2, RET, AXL, KIT, FLT-3 and TIE-2 kinases. Preclinical efficacy appears to be associated 
with its inhibitory effects against both MET and VEGFR [92]. Cabozantinib has demonstrated to be 
active in patients with HCC, NSCLC, metastatic castrate-resistant prostate cancer (CRPC) and 
metastatic medullary thyroid cancer for which this compound has been approved by regulatory 
agencies [93]. A phase II study administered cabozantinib as single agent in 44 pre-treated patients 
with locally advanced or metastatic IH or EH carcinomas. Results are expected on July 2016 
(NCT01954745). Reported toxicities of cabozantinib included fatigue, mucositis, diarrhoea, 
anorexia, nausea/vomiting, dysphonia, hypertension, hand-foot syndrome and increased risk of 
haemorrhage.  
Dasatinib (Sprycel™, Bristol-Myers Squibb) is a TKI inhibiting SRC/ABL, c-KIT, and PDGFR α 
and β [94]. In preclinical studies, it has been shown to be active against triple-negative breast 
cancer, gastric, pancreatic, head and neck, and lung cell lines [95,96]. Clinical studies have 
evaluated dasatinib activity in breast, prostate, melanoma, head and neck, and colorectal cancer 
patients. As far as CCA is concerned, a phase II trial of dasatinib in patients with isocitrate 
dehydrogenase (IDH)-mutant tumours is ongoing, primary endpoint being ORR, and main 
secondary endpoints being PFS and OS(NCT02428855). The study started on April 2015 and is 
expected to end in 2022, after having recruited 19 patients. Dasatinib was generally well-tolerated 
with side effects occurring in a small group of patients. Toxicities included abdominal pain, 
diarrhoea, nausea, vomiting, gastrointestinal bleeding, dyspepsia, pleural effusion, dyspnoea, cough, 
headache, peripheral neuropathy, left ventricular dysfunction, cardiac failure, cardiomyopathy, 
diastolic dysfunction, and QT-interval prolongation. 
 
8. Novel agents 
DKN-01 (Leap Therapeutics) is a humanized monoclonal antibody neutralizing Dickkopf-related 
protein 1 (Dkk-1) and thus inhibiting the Wnt/β-catenin pathway [97]. This drug has shown 
promising activity in preclinical studies in breast, melanoma and myeloid leukemia cell lines [98-
100]. DKN-01 is under investigation in different clinical trials, including a phase I study designed 
to evaluate safety, tolerability, pharmacokinetics, and anti-tumour activity of DKN-01 in 
combination with gemcitabine and cisplatin in patients with CCA (NCT02375880). Preliminary 
safety results of the study (dose finding – Part A) have been presented at ASCO 2016 and indicated 
300 mg as the MTD of DKN-01, with neutropenia as the main side effect. Among the three patients 
receiving the MTD of DKN-01, one obtained a clinical response and two a disease stabilization 
[101]. Study part B (expansion cohort) is ongoing and is expected to end in September 2017, after 
having enrolled 32 patients. 
Saracatinib (AZD0530, Astra Zeneca) is a Src-family (including Fyn, Lyn, and Src) kinases 
inhibitor with in vitro activity against breast, gastric, ovarian, and sarcoma cell lines as well as in 
mouse models of prostate cancer [102-104]. Saracatinib on CCA cell lines and in mouse models 
demonstrated to counteract the activation of Src and of its downstream effectors, increasing the 
fraction of cells in G(0)-G(1) phase, and inhibiting cell migration, whereas at higher concentrations 
it inhibits CCA cell proliferation. In clinical setting, sarcatinib as single agent has been tested in 
patients with breast, NSCLC, colorectal, renal, gastric, pancreatic, melanoma, and head and neck 
cancers [105-107]. The results obtained in these studies, however, were not encouraging. Thus, 
sarcatinib is currently being evaluated in combination with other target agents or conventional 
chemotherapy. The combination of sarcatinib and cediranib has been tested in a phase I study 
enrolling patients with advanced, pre-treated solid tumours including CCA. All cediranib doses 
were tolerated; however with saracatinib 175 mg/day, cediranib 20 or 30 mg/day was more 
sustainable than 45 mg/day. The most common adverse events were hypertension (67%), diarrhoea 
(62%), dysphonia (46%) and fatigue (39%). Twenty-two out of 35 evaluable patients had stable 
disease as the best clinical response [108].   
Exerin (ADH-1, Adherex Technologies) is an N-cadherin inhibitor that demonstrated some 
preclinical activity against breast, melanoma, and prostate cancer cells [109-111].In the clinical 
setting, a phase I study is evaluating the toxicity profile and the MTD of ADH-1 in combination 
with gemcitabine and cisplatin in patients with unresectable or metastatic pancreatic and CCA 
cancers (NCT01825603). The study will enrol 24 patients and it is estimated to end in 2018. 
Silmitasertib (CX-4945, Senhwa Biosciences) is an orally available highly selective inhibitor of 
CK2, a constitutively active, ubiquitous serine/threonine kinase [112]. In in vitro studies it has been 
demonstrated to be active against breast cancer and NSCLC [113]. Silmitasertib can be orally 
administered safely with some reported encouraging clinical activity as a single agent with 15% of 
the patients with disease stabilization lasting more than 6 months [114]. A phase I/II study is 
evaluating the association of silmitasertib with gemcitabine and cisplatin in the frontline treatment 
of patients with advanced CCA (NCT02128282). Results are waited for the first part of 2017. 
Mutations in mitochondrial isocitrate dehydrogenase (IDH) were shown in preclinical studies 
representing a potential target for anti-tumour agents. AG 881 (Agios and Cellgene), an orally 
available pan-IDH mutant inhibitor has shown to fully penetrate the blood-brain barrier and to 
inhibit isocitrate dehydrogenase-1 (IDH1) and IDH2 mutations in cancer models. A phase I, 
multicentre, open-label study, aimed to assess safety, pharmacokinetic, pharmacodynamics, and 
clinical activity of AG-881 in patients with advanced solid tumours, including CCA, with IDH1 
and/or IDH2 mutation is recruiting patients (NCT02481154). The study started on May 2015 and is 
expected to end in October 2018, after having enrolled 150 patients. Similarly a selective IDH1 
inhibitor (AG 120) is being evaluated in patients with advanced solid tumours (including CCA) 
harbouring IDH1 and/or IDH2 mutation (NCT02073994). Results of this study are expected for the 
end of 2016. 
OXY111A (NormOxyx) is a novel allosteric modulator of affinity of oxygen to haemoglobin, 
enhancing oxygen delivery to hypoxic tissues. OXY111A demonstrated promising results in 
preclinical studies of colorectal and pancreatic cancer [115,116]. The safety profile and the activity 
of OXY111Ais currently investigated in a phase IB/IIA study enrolling patients with hepato-
pancreato-biliary neoplasia. The trial is still recruiting patients and is expected to end on December 
2016. (NCT02528526) 
PLX 8394 is an orally available, potent and selective inhibitor of BRAF V600E exhibiting 
promising results in melanoma resistant cells [117]. Two phase I/II studies are ongoing to evaluated 
the safety profile and clinical activity of the drug in refractory, advanced solid tumours, including 
CCA. Results a are waited for 2017 (NCT02012231 - NCT02428712). 
Veliparib (ABT-888, AbbVie) is an orally bioavailable PARP-1/2 inhibitor that significantly 
potentiated the anti-neoplastic effect of several cytotoxic agents including temozolomide, platinum, 
and irinotecan in preclinical models [118,119]. In clinical studies it showed a favourable safety 
profile with encouraging clinical outcomes in colorectal, breast, prostate, melanoma, NSCLC, and 
ovarian cancer patients [120-122]. A phase I study evaluating the efficacy and safety of veliparib, 
cisplatin and gemcitabine combination therapy in patients with advanced CCA, pancreatic, 
urothelial, or NSCLC has been terminated on February 2013, but results have never been published 
yet (NCT01282333). The most frequent adverse events are thrombocytopenia, anaemia, 
neutropenia, fatigue, nausea and vomiting.  
RRx-001 (EpicentRx) is a structurally unique pharmacophore that inhibits multiple epi-enzymes 
and independently affects the apoptosis pathway and reactive oxygen and nitrogen species (RONS) 
production. RRx-001 is not cross-resistant with approved therapies and selectively targets and re-
sensitizes hypoxic tumour cells to immunotherapy, chemotherapy and radiotherapy. Moreover, 
RRx-001 modulates tumour blood flow, hypoxia and vascular function triggering apoptosis in 
cancer cells [123]. In a phase I study, RRx-001 demonstrated encouraging antitumor activity 
including re-sensitization to formerly effective chemotherapy while exhibiting a benign safety 
profile in heavily pre-treated patients with relapsed/ refractory solid tumours [124]. CCA tumours 
initially responding to cisplatin and gemcitabine and then become resistant are the target population 
of a phase II study exploring whether therapy with RRx-001 may re-sensitize tumours to the same 
cisplatin and gemcitabine regimen. RRx-001 is administered intravenously weekly, for six weeks. 
At the end of this period, chemotherapy is introduced and in case of response, is continued as long 
as tumour respond. The primary objective of this clinical trial is to evaluate PFS at 9 weeks after the 
reintroduction of gemcitabine and cisplatin. A total of 30 patients will be enrolled and the study is 
expected to end on May 2018 (NCT02452970). 
Becatecarin (Helsinn Healthcare) is a synthetic diethylaminoethyl analogue of the indolocarbazole 
glycoside antineoplastic antibiotic rebeccamycin. Becatecarin intercalates into DNA and stabilizes 
the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalysed DNA 
breakage-reunion reaction and initiating DNA cleavage and apoptosis [125]. In clinical setting, 
becatecarin has shown promising results in colorectal, renal, and lung cancer patients as well as in 
CCA patients [126]. In a phase II study enrolling patients with advanced CCA it obtained an ORR 
of 5% and a DCR of 40% [127]. Following these encouraging results, a randomized, phase III 
multicentre, open label study of becatecarin versus 5-FU plus leucovorin in 248 patients with 
advanced CAA was terminated on November 2006. (NCT00090025). Results have never been 
reported. Becatecarin was well tolerable and hematologic toxicity was the most common side 
effects. Non-hematologic toxicities were moderate and included weakness/fatigue, nausea/vomiting, 
diarrhoea and anorexia. 
 
9. Conclusion 
A large number of target agents have been explored in patients with locally advanced or metastatic 
biliary cancers (Table 3). Notwithstanding the strong biomolecular rationale and preclinical results, 
none of them have demonstrated a sufficient clinical activity to be authorized in the clinical routine. 
Several reasons may account for these disappointing results. First of all, CCA is a rare neoplasms 
and thus enrolment of a large number of patients is arduous. As a consequence, it is easier to 
demonstrate a clinical activity of an antineoplastic compounds with a less specific mechanism of 
action rather than a target therapy that may be beneficial only in a selected subpopulation of 
patients. In this sense, in an unselected population multitarget TKI should be more beneficial than 
specific inhibitors. However, preliminary results of vandetanib did not demonstrate superiority of 
the drug when compared to chemotherapy. Moreover, the low number of patients prompted 
researchers to enrol in their studies all CCA patients, regardless of the site of the tumour. This may 
jeopardize results as the mutational status of intrahepatic, extrahepatic and gallbladder cancers are 
not similar. In a recent work presented at ASCO 2016, in fact, it has been shown that MET 
overexpression was detected only in intrahepatic CCA, whereas extrahepatic CCA were more 
frequently RAS mutated and gall bladder carcinomas were more frequently HER2 amplified [128]. 
Thus, any target therapy administered without a patient selection according to the biological tumour 
profile may results in different outcomes simply on the basis of unbalances between these three 
groups of tumours. 
In conclusion, while waiting for novel compounds with interesting mechanisms of action, no new 
agent improved clinical outcome of locally advanced or metastatic CCA patients either as single 
agent or combined to chemotherapy. A better biological characterization of these tumours is 
fundamental to guide new clinical trial. 
 
10. Expert opinion 
Cholangiocarcinoma is a rare neoplasm harbouring complex and multiple gene mutations and/or 
expressions. Thus, beside the well-established role of chemotherapy several specific inhibitors have 
been tested. The most studied compounds are cetuximab and panitumumab. Unfortunately, these 
anti-EGFR monoclonal antibodies did not confirm exciting preclinical findings. One possible 
explanation for these disappointing results may relay on the lack of a patient selection. Making a 
parallelism with the scientific history of anti-EGFR antibodies in the treatment of patients with 
advanced colorectal cancers, first results in an unselected population were unsatisfactory. However, 
drug efficacy was dramatically improved after selection according to KRAS and then to NRAS 
status. In CCA patients, cetuximab was tested in patients regardless their RAS status. Some Authors 
tried to make a retrospective subgroup analysis, however comparison were made with very limited 
number of patients and thus results has to be considered as inconclusive. Panitumumab was tested 
in patients with KRAS wild type tumours. Notwithstanding this patient selection, results were 
negative. It is a good matter of debate wondering whether these disappointing findings would have 
been comparable in a RAS wild type population. Another possible explanation could be the choice 
of the biomolecular marker. It has been recently published a comprehensive review in which EGFR 
expression has been identified as a prognostic parameter [129]. This finding is very interesting as it 
gives rise to an intriguing question: should we continue to stratified CCA patients according to the 
RAS status or should we group patients according to EGFR expression? And in this latter case, 
which could be the positivity threshold? Future researches should be directed in defining predictive 
indicators for anti-EGFR therapies. 
Beside some positive findings obtained with anti-EGFR therapy, no striking results are waited for 
the novel therapies currently tested and summarized in Table 3. No clinically relevant outcomes 
have been described for anti-HER2, anti-VEGF, anti-ABL agents and mTor inhibitors. Continuing 
the parallelism with colorectal cancer, some promising preliminary activity could be waited for the 
multitarget TKIs such as regorafenib, cabozantinib, merestinib, and dasatinib. In fact, while specific 
inhibitors (for instance anti-EGFR and anti-VEGF) had to be combined with chemotherapy, these 
multitarget compounds demonstrated to be active when administered as single agents. Finally, 
despite interesting mechanisms of action, no outstanding results are waited for the novel compounds 
listed at the end of Table 3. 
In this rare neoplasm the future challenge is the discovery of biomolecular alterations which drive 
tumour progression and aggressiveness in order to focus on selected patients avoiding resource 
consuming and wasting. In this sense, next-generation sequencing (NGS) survey of biliary tract 
cancers may help in determining which is the leading mutation of each single tumour, permitting 
physician to personalize therapy in the very next future. Some correlations between NGS and 
clinical outcome have already been reported [130]. The limitation of this techniques is mainly the 
cost. However, the standardization of a panel of genetic alteration automatically detected may 
reduce costs permitting to a larger spectrum of tumours to be analysed [131]. Some exciting data 
are already available for NSCLC patients [132]. This technique will also facilitate the description of 
possible multiple mutations driving tumour progression requiring various specific inhibitions and, 
maybe, the mechanisms of acquired drug resistance. 
The main limitation of patient selection according to relative rare gene mutations is that accrual of a 
particular population of CCA patients is somehow impossible without the involvement of a large 
number of institutions. As a consequence, when designing a new trial researchers must choose 
whether collaborate with a large number of institutions (thing often difficult and expensive in 
practice) or enrol unselected patients (easier in practice). Testing a new compound in an unselected 
population, however, could result in negative results even if a particular agent is very active in a 
particular subgroup of patients. Thus, it could be hypothesized that some novel therapies already 
explored in unselected patients and considered as ineffective could be very active in selected ones. 
This was the case, for instance, for gefitinib in EGFR mutated adenocarcinoma of the lung. Thus, 
even though international collaborations are difficult, this will be the best way to explore particular 
gene inhibition. Some trials have been designed in this sense, aiming to explore the clinical 
usefulness of specific inhibitors in selected patients (such as those with tumours harbouring ALK, 
ROS1, FGFR, NTRK, and IDH genetic alterations). Although many of these studies will screen a 
large population to enrol a relative small number of patients, their results will be very interesting 
and will pave the way for new stimulating clinical trials. 
Finally, immunotherapy has gain extreme importance in the last few years, especially in patients 
bearing metastatic melanoma, renal cell carcinoma and other several solid tumours. It will be of 
great interest to explore whether this class of agents may be beneficial also in patients with CCA.  
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 Table 1. Key results of trials exploring cetuximab in locally advanced or metastatic CCA patients 
Author, year 
[ref] 
Schedule Phase # patients Results Primary 
aim 
Met? 
Chang, 2010 
[8] 
Cet-
containing 
chemo 
Retrospective 5 1 CR + 3 PR + 1 SD 
PFS 4-16 months 
NA 
Borbath, 
2013 [9] 
Cet + Gem II 44 6 months PFS = 47% 
OS = 13.5 months 
ORR = 20.4% 
DCR = 79.5% 
6 months 
PFS  
Met 
Malka, 2014 
[10] 
GEMOX ± 
Cet 
II 
Randomised  
150 GEMOX vs GEMOX + Cet 
PFS = 5.5 vs 6.1 months 
OS = 12.4 vs 11.0 months 
NA 
Paule, 2007 
[11] 
GEMOX + 
Cet  
Retrospective 9 In IH CCA only GEMOX pretreated 
2 PR (ORR = 22%) 
NA 
Gruenberger, 
2010 [12] 
GEMOX + 
Cet 
II 30 60% of the patients had IH CCA 
ORR = 63% 
ORR 
Met 
Chen, 2015 
[13] 
GEMOX ± 
Cet 
II 
Randomised 
122 GEMOX + Cet vs GEMOX 
ORR = 27% vs 15% (p=0.12) 
PFS = 6.7 vs 4.1 months (p=0.05) 
OS = 10.6 vs 9.8 months (p=0.91) 
ORR 
Not Met 
Cet = Cetuximab; Gem = Gemcitabine; GEMOX = Gemcitabine and oxaliplatin; ORR = Overall Response Rate; 
DCR = Disease Control Rate; CR = Complete Response; PR = Partial Response; SD = Stable Disease; OS = 
Overall Survival; PFS = Progression Free Survival; NA = Not Assessable 
CCA = Cholangiocarcinoma; IH = Intrahepatic 
 
 Table 2. Key results of trials exploring panitumumab in locally advanced or metastatic CCA patients 
Author, year  
[ref] 
Schedule Phase # patients Results Primary 
aim 
Met? 
Jensen, 2012 
[15] 
GEMOX + 
Pan + 
Capecitabine 
II 46 KRAS 
wt 
6-month PFS = 71% 
PFS = 8.3 months 
ORR = 33% 
DCR = 86% 
OS = 9.8 months 
6-month 
PFS  
Met 
Hezel, 2014 
[16] 
GEMOX + 
Pan 
II 31 KRAS 
wt 
ORR = 45% 
PFS = 10.6 months 
OS = 20.3 months 
ORR 
Not Met 
Sohal, 2013 
[17] 
Gem + Pan + 
irinotecan 
II 35 5-month PFS = 69% 
ORR = 31% 
PFS = 9.7 months 
OS = 12.9 months 
5-month 
PFS 
Met 
Leone, 2016 
[18] 
GEMOX ± 
Pan 
II 
Randomised 
89 KRAS 
wt 
GEMOX + Pan vs GEMOX 
PFS = 5.3 vs 4.4 months (p= 0.27) 
OS = 9.9 vs 10.2 months  (p=0.42) 
ORR = 26.7% vs 18.2% (p=0.99)  
PFS 
Not Met 
Pan = Panitumumab; Gem = Gemcitabine; GEMOX = Gemcitabine and oxaliplatin; wt = wild type;  ORR = 
Overall Response Rate; DCR = Disease Control Rate; CR = Complete Response; PR = Partial Response; SD = 
Stable Disease; OS = Overall Survival; PFS = Progression Free Survival; NA = Not Assessable 
CCA = Cholangiocarcinoma; IH = Intrahepatic 
 
 Table 3. New agents under evaluation in CCA patients grouped according to inhibition target or novelty of 
action 
Drug Class 
Target 
Stage of 
development in 
CCA 
Note 
HER Family 
Cetuximab Ab Random Phase II Not superior to CT alone 
Panitumumab Ab Random Phase II Not superior to CT alone 
Erlotinib TKI Phase III Not superior to CT alone 
Trastuzumab Ab Phase II Ongoing. Slow accrual 
Lapatinib TKI Phase II Abandoned 
ASLAN001 TKI Phase II Ongoing 
mTOR 
Everolimus Small mol Phase II Results not clinically relevant 
VEGF 
Bevacizumab Ab Phase II Not approved 
Ramucirumab Ab Phase II Ongoing. No result posted 
Cediranib TKI Random Phase II Not superior to CT alone 
Regorafenib TKI Phase II Ongoing 
Sorafenib TKI Two-step Phase II Terminated after first step. No 
clinical activity 
Sunitinib TKI Phase II Ongoing 
Pazopanib TKI Phase II Ongoing 
FGFR 
Infigratinib TKI Phase II Ongoing 
ARQ087 TKI Phase II Ongoing in solid tumours 
including CCA 
ALK 
Ceritinib TKI Phase II Ongoing in ROS1/ALK over-
expressed CCA 
Entrectinib TKI Phase I/II Ongoing in solid tumours with 
NTRK1-3, ROS or ALK molecular 
alterations 
ABL 
Bosutinib TKI Phase II Abandoned 
Imatinib TKI Phase II Low clinical activity. Abandoned 
MEK 
Trametinib TKI Phase II Waiting for results 
Selumetinib TKI Phase I Phase II not yet proposed 
PI3K AKT 
Buparlisib Small mol Phase II Lack of accrual in solid tumours. 
Not in development 
MK2206 Small mol Phase II Limited clinical activity 
FARNESYLTRANSFERASE 
Lonafarnib Small mol Phase II Protocol withdrawn before 
enrolment 
Tipifarnib Small mol Phase I Not more in development 
PROTEASOME 
Bortezomib Small mol Two-step Phase II Terminated after first step. 
Limited clinical activity 
MULTITARGET 
Vandetanib TKI Random Phase II Not superior to CT alone 
Merestinib TKI Phase II Ongoing 
Cabozantinib TKI Phase II Ongoing 
Dasatinib TKI Phase II Ongoing in IDH-mutant CCA 
NOVEL AGENTS 
DKN-01 Ab antiDkk-1 Phase I/II Ongoing with cisplatin + gem 
Saracatinib TKI binding to Src Family Phase I MTD determined in solid 
tumours, including CCA 
Exerin N-cadherin inhibitor Phase I Ongoing with cisplatin + gem 
Silmitasertib CK2 (serine/threonine 
kinase) inhibitor 
Phase I/II Ongoing with cisplatin + gem 
AG881 Pan-IDH mutant 
inhibitor 
Phase I Ongoing in solid tumours, 
including CCA 
OXY111A Oxygen modulator Phase I/II Ongoing 
PLX 8394 BRAF inhibitor Phase I/II Ongoing 
Veliparib PARP 1/2 inhibitor Phase I With cisplatin + gem. No results 
have been published 
RRx-001 Multiple epi-enzyme 
inhibitor 
Phase II Ongoing with cisplatin + gem 
Becatecarin Topoisomerase I 
inhibitor 
Phase III Trial terminated in 2006. No 
results available 
 
 
 
